0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Ixazomib in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2016-11-21
EMA conditional? :
Yes
EMA orphan? :
Yes
EMA biological? :
No